rethinkPeptides Search
Menu
Home / Research library
Study breakdown

BPC-157 Heals Both Colon and Duodenal Damage From Cysteamine Without Needing Stomach Acid

RPEP-006972001Sikiric, P; Seiwerth, S; Grabarevic, Z; Balen, I; Aralica, G; Gjurasin, M; Komericki, L; Perovic, D; Ziger, T; Anic, T; Prkacin, I; Separovic, J; Stancic-Rokotov, D; Lovric-Bencic, M; Mikus, D; Staresinic, M; Aralica, J; DiBiaggio, N; Simec, Z; Turkovic, B; Rotkvic, I; Mise, S; Rucman, R; Petek, M; Sebecic, B; Ivasovic, Z; Boban-Blagaic, A; Sjekavica, I
Animal StudyPreliminary evidence
The takeaway

BPC-157 healed cysteamine-induced colon and duodenal lesions in rats, including in gastrectomized animals, proving its healing mechanism is independent of gastric acid reduction.

No acid needed

BPC-157 healed gut lesions in gastrectomized rats — no stomach, no acid, but still complete healing. Its mechanism is fundamentally different from antacids.

What the researchers found

BPC-157 attenuated cysteamine-induced colon and duodenal lesions, including in gastrectomized rats, demonstrating acid-independent healing and extending its protective effects to the entire gut.

Why it matters

Showing BPC-157 heals gut damage without needing acid reduction proves it works through a fundamentally different mechanism from conventional GI drugs — potentially applicable to conditions where acid isn't the problem.

How the study worked

Animal study in naive and gastrectomized rats. Cysteamine-induced duodenal and colon lesions treated with BPC-157, cimetidine, ranitidine, omeprazole, sucralfate, and others. Lesion healing compared across acid-present and acid-absent conditions.

What this study cannot tell us

Rat model. Cysteamine-induced lesions may not perfectly model clinical gut diseases. The specific acid-independent mechanism was not identified.

How to read the evidence

Preliminary animal evidence with the elegant experimental control of gastrectomized animals proving acid independence.

When this study was published

Published in 2001. BPC-157's acid-independent gut healing has been confirmed and is now considered a defining feature of its pharmacology.

The bigger picture

Inflammatory bowel disease, colitis, and many gut conditions involve damage unrelated to acid. BPC-157's acid-independent healing makes it relevant for conditions that acid-reducing drugs can't address.

Questions still open

  • Could BPC-157 treat ulcerative colitis or Crohn's disease?
  • What is the acid-independent healing mechanism?
  • Does BPC-157's colon healing involve the same angiogenic mechanism as its gastric healing?

Common questions

Why does healing without acid matter?
Most gut drugs work by reducing acid. But many gut conditions (colitis, Crohn's, IBD) aren't caused by acid. BPC-157's acid-independent healing means it could treat conditions that antacids can't.
Could BPC-157 treat IBD?
Its ability to heal both colon and duodenal damage without relying on acid reduction makes it a strong candidate for IBD research. The acid-independent mechanism is exactly what's needed for inflammatory bowel conditions.

Read the original research

Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone.

Journal of physiology, Paris, 95(1-6), 261-70

View on PubMed ↗

Citation

Sikiric, P; Seiwerth, S; Grabarevic, Z; Balen, I; Aralica, G; Gjurasin, M; Komericki, L; Perovic, D; Ziger, T; Anic, T; Prkacin, I; Separovic, J; Stancic-Rokotov, D; Lovric-Bencic, M; Mikus, D; Staresinic, M; Aralica, J; DiBiaggio, N; Simec, Z; Turkovic, B; Rotkvic, I; Mise, S; Rucman, R; Petek, M; Sebecic, B; Ivasovic, Z; Boban-Blagaic, A; Sjekavica, I. (2001). Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone.. Journal of physiology, Paris, 95(1-6), 261-70.